James Abraham, a 30-year veteran of the medical device world, is the new chief operating officer of Noblesville, Indiana-based Nexxt Spine, LLC. A spine expert, Abraham joins the company at a time of growth, including several FDA 510(k) clearances, products launches, and planned launches.
James Abraham: New COO of Nexxt Spine

Most recently Abraham was managing director/vice president of NuVasive, Inc.’s Australia and New Zealand regions. Other positions include general manager, executive vice president and senior director at Amedica, Stryker, and IsoTis Orthobiologics. Abraham has experience in a wide range of arenas, including sales, marketing, operations, business development, product/project management and acquisition. He is on the board of OSTI Inc. Panama, Sandhills Investment Group LLC and the Patrick Michaels Group LLC.
“We are proud to welcome James to the Nexxt Spine family,” says President Andy Elsbury. “We believe he is the perfect executive to build on our success and seize the opportunities ahead.”
Abraham told OTW, “My roles at NuVasive and Stryker prepared me best for this role as COO at Nexxt Spine in two distinctly different ways. In my last position at NuVasive as Managing Director/VP of Australia/New Zealand I was able to have responsibility for the internal operations and external customer facing teams. This helped me integrate the two and develop leadership skills in both areas. The last role at Stryker as Director of Development provided me with learning how to work through others without authority or a reporting line and how to create personal and professional development plans along with succession planning and short- and long-term planning for rapid organizational growth.”
Asked about his current activities, Abraham explained, “The first steps are underway, which is my developing an understanding of the current processes we utilize for customer service, distribution services, hospital consignment and loaner instrument systems. The goal is to look for efficiencies and streamline our operations in order to sustain and build upon Nexxt Spine’s rapid growth. In addition, I will be accessing our global distributor channels and go-to-market strategies for our current products and new product introductions. Finally, I will be leading our efforts to build out the remainder of a 2020 plan after the COVID pandemic and how we move into the 2021 business model and creating with our management team a 3- to 5-year business model.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.